Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer.

Aslamuzzaman KaziLiwei ChenShengyan XiangRajanikanth VangipurapuHua YangFrancisca BeatoBin FangTerence M WilliamsKazim HusainPatrick W UnderwoodJason B FlemingMokenge MalafaEric A Welsh John M KoomenJosé TrevinoSaïd M Sebti

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

A link between CDK hyperactivation and mt KRas dependency was uncovered and pharmacologically exploited to abrogate mt KRas-driven pancreatic cancer in highly relevant models, warranting clinical investigations of AT7519 in patients with pancreatic cancer.

Keyphrases

wild type
cell cycle
climate change
genome wide
gene expression
single cell